BIO Submits Comments on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses Proposed Rule
March 20, 2019
BIO submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed rule, Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses Proposed Rule.
BIO is extremely concerned the Agency continues to erode the value of the Medicare benefit for seniors, placing patient access at risk. This proposed rule prioritizes cost containment policies over patient healthcare needs. BIO respectfully requests the Agency and Administration instead focus on holistic solutions to balance the financial sustainability of the Medicare program, while addressing patient out-of-pocket cost and access to appropriate treatment. In the comments, BIO provides specific recommendations for how CMS can improve the proposed rule and ensure greater access for patients while directly reducing OOP costs.
Download Full Comments Below
FINAL BIO Comment Letter MA And Part D Proposed Rule 1 25 19
BIO submits comments on the MDH’s proposed regulations regarding Drugs of Substantial Public Interest: Draft Methodology for Public Comment as required in statute by the Prescription Drug Price Transparency Act.
The Biotechnology Innovation Organization appreciates the opportunity to comment on the Center for Medicare and Medicaid Services’ Information Collection Request on the Part C and Part D Medicare Prescription Payment Plan Model Documents.
BIO submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed rule, Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses Proposed Rule.
BIO is extremely concerned the Agency continues to erode the value of the Medicare benefit for seniors, placing patient access at risk. This proposed rule prioritizes cost containment policies over patient healthcare needs. BIO respectfully requests the Agency and Administration instead focus on holistic solutions to balance the financial sustainability of the Medicare program, while addressing patient out-of-pocket cost and access to appropriate treatment. In the comments, BIO provides specific recommendations for how CMS can improve the proposed rule and ensure greater access for patients while directly reducing OOP costs.